Pre-surgery targeted therapy guided by genetic changes for advanced thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of thyroid cancer that is advanced or has spread and cannot be cured by surgery alone.
- Your tumor must have one of the specific genetic changes or markers listed (like BRAF, RET, NTRK, PD-L1) — your doctor can check your tests.
- You need to be able to manage daily activities with some help (ECOG 0-2).
- You must have at least one tumor that can be measured for response, or for medullary cancer, certain blood tests (calcitonin/CEA) that can be tracked.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
Hear when a new Thyroid Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.